Health Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS James Pereira Apr 26, 2023 <!-- Name:DistributionId Value:8825434 --> <!--… Read More...
Health FDA advisors vote against effectiveness of Biogen’s ALS drug for rare and aggressive form of… James Pereira Mar 23, 2023 A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021.Adam… Read More...
Health FDA advisors reject Biogen’s ALS drug for rare and aggressive form of the disease James Pereira Mar 23, 2023 A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021.Adam… Read More...
Health FDA staff says Biogen’s ALS drug may have a ‘clinical benefit’ on a rare form of… James Pereira Mar 21, 2023 U.S. Food and Drug Administration staff on Monday said Biogen's investigational ALS drug may have a "clinical benefit"… Read More...
Health FDA will review Eisai’s and Biogen’s Alzheimer’s treatment Leqembi with decision… James Pereira Mar 6, 2023 Andrew Brookes | Image Source | Getty ImagesThe Food and Drug Administration will make a decision on whether to fully… Read More...
Business Biogen’s Stock Pullback Offers a Second Chance Nick J Adam Oct 18, 2022 After slipping to its lowest level since 2013, Biogen Inc. (NASDAQ:BIIB) was all but forgotten by growth… Read More...
Health Here’s why Biogen’s promising Alzheimer’s drug data is also good news for Eli… James Pereira Sep 29, 2022 We don't own Eli Lilly exclusively for its potential Alzheimer's treatment. However, we still find Biogen's topline data… Read More...
Health The FDA approved a new drug to treat Alzheimer’s, but Medicare won’t always pay for it –… James Pereira Apr 14, 2022 Medicare finalized its decision to restrict its coverage of Aduhelm, Biogen’s new Alzheimer’s disease drug, on… Read More...
Health New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research… James Pereira Apr 5, 2022 Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as… Read More...
Business Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients Nick J Adam Jan 12, 2022 Medicare officials said they would cover Biogen Inc.’s BIIB 2.64%… Read More...